|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126439 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-09 11:31:14 |
|
注册时间: Date of Registration: |
2026-06-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
“数字+信任”双赋能混合干预提升婴幼儿流感疫苗接种率的整群随机对照试验与实施性研究 |
|
Public title: |
A cluster randomized controlled trial and implementation study of "digital + trust" dual-empowerment mixed intervention to improve influenza vaccination coverage in infants and young children |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
“数字+信任”双赋能混合干预提升婴幼儿流感疫苗接种率的整群随机对照试验与实施性研究 |
|
Scientific title: |
A cluster randomized controlled trial and implementation study of "digital + trust" dual-empowerment mixed intervention to improve influenza vaccination coverage in infants and young children |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨玲 |
研究负责人: |
杨玲 |
|
Applicant: |
Ling yang |
Study leader: |
Ling yang |
|
申请注册联系人电话: Applicant telephone: |
+86 158 8802 5908 |
研究负责人电话: Study leader's telephone: |
+86 158 8802 5908 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tangkatang@163.com |
研究负责人电子邮件: Study leader's E-mail: |
tangkatang@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江宁波百丈东路251号 |
研究负责人通讯地址: |
中国浙江宁波百丈东路251号 |
|
Applicant address: |
No. 251 Baizhang East Road, Ningbo, Zhejiang, China |
Study leader's address: |
No. 251 Baizhang East Road, Ningbo, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
宁波大学附属人民医院 |
||
|
Applicant's institution: |
Ningbo University Affiliated People's Hospital |
||
|
研究负责人所在单位: |
宁波大学附属人民医院 |
||
|
Affiliation of the Leader: |
Ningbo University Affiliated People's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
宁大附人伦审2026研第066号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宁波大学附属人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of The Affiliated People's Hospital of Ningbo University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-29 00:00:00 |
||
|
伦理委员会联系人: |
陆滢 |
||
|
Contact Name of the ethic committee: |
Lu Ying |
||
|
伦理委员会联系地址: |
中国浙江宁波百丈东路251号 |
||
|
Contact Address of the ethic committee: |
No. 251 Baizhang East Road, Ningbo, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 134 8609 0834 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
宁波大学附属人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Ningbo University Affiliated People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国浙江宁波百丈东路251号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 251 Baizhang East Road, Ningbo, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
宁波市鄞州区科学技术局 |
||||||||||||||||||||||
|
Source(s) of funding: |
Ningbo Yinzhou District Bureau of Science and Technology |
||||||||||||||||||||||
|
Target disease: |
influenza |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
整群随机分组 |
||||||||||||||||||||||
|
Study design: |
Cluster randomization |
||||||||||||||||||||||
|
研究目的: |
主要目的:在一个基线接种率约6%的街道,验证“数字+信任”混合干预策略相较于常规服务能否显著提升婴幼儿流感疫苗接种率。 次要目的:评估该混合干预模式的实施可行性、保真度与增量成本;形成标准化社区实践工具包。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Objective: To verify whether the "digital + trust" mixed intervention strategy can significantly increase the influenza vaccination rate among infants and young children compared with routine services in a subdistrict with a baseline vaccination rate of approximately 6%. Secondary Objectives: To assess the implementation feasibility, fidelity and incremental costs of this mixed intervention model; to develop a standardized community practice toolkit. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 户籍或常住(居住 >= 6 个月)于目标街道内研究社区; 2. 研究启动时年龄为 6-35 月龄; 3. 尚未接种 2026-2027 流感季流感疫苗; 4. 监护人能够理解研究内容并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Household registration or permanent residence (residing for >= 6 months) in the study community within the target subdistrict; 2. Aged 6-35 months at the start of the study; 3. Not yet vaccinated against influenza for the 2026-2027 influenza season; 4. Guardian able to understand the study content and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 既往对流感疫苗或其任何成分有严重过敏史; 2. 存在疫苗接种禁忌症(如格林-巴利综合征病史等); 3. 计划在研究期间迁出本街道。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. A history of severe allergic reactions to influenza vaccines or any of their components; 2. Presence of contraindications to vaccination (such as a history of Guillain-Barré syndrome); 3. Planning to move out of this street during the study period. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-06-19 00:00:00 至 To 2027-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用区组随机化方法。以社区卫生服务中心为分层因素(本街道仅一家中心,分层后仅一层),在该层内采用区组随机化,区组长度随机变化(4或6),按1:1比例将社区分配至混合干预组和常规服务对照组。最终分配结果为干预组6个社区、对照组5个社区。随机序列由不参与现场招募的统计师使用R软件(版本4.3,设置随机种子)生成。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Block randomization method was adopted. The community health service center was taken as the stratification factor (there is only one center in this sub-district, leaving only one stratum after stratification). Within this stratum, block randomization was applied with randomly varied block sizes (4 or 6). Communities were allocated to the combined intervention group and the routine service control group at a 1:1 ratio. The final allocation resulted in 6 communities in the intervention group and 5 communities in the control group. The random sequence was generated by a statistician not involved in on-site recruitment using R software (Version 4.3, with a random seed set). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究为开放标签设计,干预实施者和受试者均知晓分组。但结局指标评估采用盲法:从免疫规划信息系统提取接种记录的数据管理员和进行统计分析的分析师,在数据锁定和分析完成前均不知晓社区分组归属。 |
|
Blinding: |
This study adopts an open-label design, in which both intervention implementers and participants are aware of the group allocation. However, blinding is applied to the evaluation of outcome indicators: data administrators who extract vaccination records from the immunization information system and analysts conducting statistical analysis remain unaware of the community group assignments until data locking and analysis are completed. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:本研究通过“浙江省免疫规划信息系统”获取研究对象的流感疫苗接种记录。数据采集由经过培训的研究助理负责,采用盲法提取(提取人员不参与分组过程),确保数据的客观性。采集的内容包括:目标社区6-35月龄婴幼儿的流感疫苗接种状态(是否接种、接种剂次、接种日期)及基本人口学信息(性别、月龄、居住社区)。过程监控数据(短信平台推送成功率、点击率,社区医生结构化推荐扫码记录)由系统自动生成并导出。 数据管理:(1)数据存储:所有电子数据存储于医院的加密服务器中,仅课题组成员可凭授权账号访问。纸质材料(如问卷纪录、扫码登记表)存放于上锁的文件柜中。(2)数据保密:所有数据去除个人身份标识(姓名、身份证号、家庭住址等),仅以研究ID编号进行识别。数据导出和处理过程中严格保护参与者隐私。(3)数据使用:数据仅用于本研究所述的科学目的,不用于其他商业用途或未经批准的二次研究。(4)数据期限:研究结束后,数据将保存5年,期满后将按医院规定进行匿名化处理或销毁。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data Collection: This study obtained influenza vaccination records of research subjects through the "Zhejiang Provincial Immunization Planning Information System". Data collection was undertaken by trained research assistants with blinded extraction (extractors did not participate in the grouping process) to ensure the objectivity of the data. The collected information included the influenza vaccination status (vaccination status, number of doses, vaccination date) and basic demographic information (gender, age in months, residential community) of infants aged 6 to 35 months in target communities. Process monitoring data (short message platform push success rate, click rate, structured recommendation QR code scanning records by community doctors) were automatically generated and exported by the system. Data Management: (1) Data Storage: All electronic data are stored on the hospital's encrypted servers, accessible only to research team members via authorized accounts. Paper materials (such as questionnaire records and QR code registration forms) are kept in locked filing cabinets. (2) Data Confidentiality: All personal identifiers (name, ID number, home address, etc.) are removed from the data, and participants are identified only by research ID numbers. Participants' privacy is strictly protected during data export and processing. (3) Data Usage: The data shall only be used for the scientific purposes stated in this study and shall not be used for other commercial purposes or unauthorized secondary research. (4) Data Retention Period: After the completion of the study, the data will be retained for 5 years. Upon expiration, the data will be anonymized or destroyed in accordance with hospital regulations. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |